Self-Assembled Particles Combining SARS-CoV-2 RBD Protein and RBD DNA Vaccine Induce Synergistic Enhancement of the Humoral Response in MiceArticle Published on 2022-02-162022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, [키워드] antibody approach Cellular immune response cellular response characterized Combination components coronavirus vaccine COVID-19 DNA DNA vaccine domain effective enhancement filtration gel highest humoral Humoral response IgG immunized increase mice Microscopy Neutralizing activity Particle Particles Protein RBD RBD protein response Safe SARS-CoV-2 SARS-CoV-2 RBD self-assembled particles significantly lower the spike protein vaccination Vaccine virus-neutralizing activity [DOI] 10.3390/ijms23042188 PMC 바로가기 [Article Type] Article
Incidence, Pattern and Severity of Adverse Events Following Immunization (AEFIs) Associated With Chadox1 nCOV-19 Corona Virus Vaccine (Recombinant) Among the Healthcare Workers of a Tertiary Care Institute of Eastern Uttar Pradesh, IndiaInfectious Disease Published on 2022-02-022022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Adverse adverse event aefis authorisation Bharat Care ChAdOx1 nCoV-19 chadox1 ncov-19 corona virus vaccine cohort study Controller Corona coronavirus vaccine country COVID-19 vaccine drug Emergency use EUA first dose Government of India group healthcare worker Healthcare workers immunization incidence India injection majority nausea/vomiting observation pattern produced recombinant Result Safe Safety severity Tertiary the vaccine the WHO vaccination Vaccine Vaccines were given worker [DOI] 10.7759/cureus.21848 PMC 바로가기 [Article Type] Infectious Disease
Acute Myocardial Infarction After Coronavirus Vaccine: A Rare Adverse EffectCardiology Published on 2022-01-242022-10-31 Journal: Cureus [Category] COVID-19, [키워드] Acute Adverse carried coronary syndrome coronavirus coronavirus disease coronavirus vaccine COVID-19 descending Diagnosis discharged Effect event first dose high-risk patient Hospital stay ischemic heart disease male medications Moderna Myocardial infarction Pain pandemic Patient Percutaneous coronary intervention prevented receiving Side effect the patient the vaccine triggered vaccination Vaccine was done [DOI] 10.7759/cureus.21544 PMC 바로가기 [Article Type] Cardiology
Humoral and T-cell responses to SARS-CoV-2 vaccination in multiple sclerosis patients treated with ocrelizumab오크렐리주맙으로 치료받은 다발성 경화증 환자에서 SARS-CoV-2 백신 접종에 대한 체액 및 T 세포 반응Article Published on 2022-01-012022-09-11 Journal: Multiple sclerosis and related disorders [Category] MERS, SARS, 진단, 치료기술, [키워드] Absolute lymphocyte count adaptive Adaptive Biotechnology age analyzed anti-CD20 therapy Anti-SARS-CoV-2 S antibodies antibody Antibody Response B and T-cell BMI CD19 characterized chemotherapeutic agents cohort study comparator conducted coronavirus coronavirus vaccine COVID COVID-19 COVID-19 epidemic Descriptive statistics detectable determine did not produce Efficacy Elecsy Eligible patients enrolled Enrollment evaluate Fisher Fisher's exact test had no humoral Humoral response IgG immune response immunoassay immunogenicity Immunoglobulin Immunoglobulin G immunosuppressive impair Infection likelihood lymphocyte Multiple multiple sclerosis Natalizumab negative antibody response no correlation Ocrelizumab Patient patients patients treated positive positive antibody response post vaccination Prevent producing question raise reduce Research response Roche SAR-CoV-2 SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination SARS-CoV-2. severity Sex shown single center T-cell T-cell Response T-cell responses Test the antibody response treated Treatment vaccination Vaccine vaccine immunogenicity variable was performed were excluded Wilcoxon rank sum [DOI] 10.1016/j.msard.2021.103382 PMC 바로가기 [Article Type] Article
Occurrence of COVID-19 in priority groups receiving ChAdOx1 nCoV-19 coronavirus vaccine (recombinant): A preliminary analysis from north IndiaChAdOx1 nCoV-19 코로나바이러스 백신(재조합) 접종 우선 그룹에서 COVID-19 발생: 인도 북부에서 예비 분석Observational Study Published on 2022-01-012022-09-11 Journal: Journal of medical virology [Category] SARS, 변종, 임상, [키워드] Analysis approved breakthrough breakthrough infections cardiac ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Complete complications coronavirus vaccine COVID-19 death demonstrated dose doses Effectiveness Efficacy events Follow-up group groups healthcare Healthcare workers India majority measure Mild observational study Occurrence Oxford participant prospective observational study real world. receiving recipient Research SARS-COV-2 infection Sepsis single dose symptomatic symptomatic COVID-19 the vaccine Trial vaccination Vaccine variants Zeneca [DOI] 10.1002/jmv.27320 PMC 바로가기 [Article Type] Observational Study
Will Africans take COVID-19 vaccination?Research Article Published on 2021-12-012022-10-28 Journal: PLoS ONE [Category] COVID-19, SARS, [키워드] accelerated Administered African approval Arabic asked Coronavirus infection coronavirus vaccine country COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines cross-sectional demographics determinant Diaspora distribution English expressed French Health status individual Infection infection risk knowledge limit mandatory offer participant Perceived risk provided receive risk risk of infection sick Side effects the vaccine Treatment unique Vaccine Vaccine hesitancy Vaccines [DOI] 10.1371/journal.pone.0260575 PMC 바로가기 [Article Type] Research Article
Cutaneous reactions to COVID‐19 vaccine at the dermatology primary careShort Report Published on 2021-11-272022-10-30 Journal: Immunity, Inflammation and Disease [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Abstract Adverse reaction Adverse reactions arising Awareness bullous Care Coronavirus disease 2019 coronavirus vaccine COVID‐19 COVID‐19 skin COVID‐19 urticaria COVID‐19 vaccination reaction COVID‐19 vaccine rash cutaneous reaction Dermatology Diseases examined Future groups help Hospitalization immune responses incidence Mild moderate occurred Patient patients primary care promote raised rashe reaction Reactions recognize reduce reported required Result treat vaccination Vaccine vaccine allergy vaccine dose [DOI] 10.1002/iid3.568 PMC 바로가기 [Article Type] Short Report
Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021Research Published on 2021-11-242022-10-27 Journal: Archives of Public Health [Category] COVID-19, [키워드] 95% CI administration adverse event adverse events Analysis antipyretics AOR being ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine conducted coronavirus disease coronavirus vaccine COVID-19 cross-sectional defined enrolled Factor female females Fever first dose headache Health Health professionals Hospitalization Hospitalized injection site pain interquartile male management median age Medical doctor participant Participants performed Prevalence professional questionnaire receiving reported Result resulting SAE SAEs severe adverse event significance level Sociodemographic the vaccine These data Togo vaccination Vaccine Vaccine hesitancy was used [DOI] 10.1186/s13690-021-00741-x PMC 바로가기 [Article Type] Research
Analysis of SARS-CoV-2 haplotypes and genomic sequences during 2020 in Victoria, Australia, in the context of putative deficits in innate immune deaminase anti-viral responses2020년 호주 빅토리아에서 SARS-CoV-2 일배체형 및 게놈 서열 분석Article Published on 2021-11-012022-09-11 Journal: Scandinavian journal of immunology [Category] SARS, 변종, [키워드] ADAR analysed Analysis Anti-viral anti-viral response anti-viral responses APOBEC APOBEC and ADAR deamination motifs Care cascades coronavirus vaccine COVID‐19 COVID‐19 haplotypes curated Data analysis Deamination death deficiency Department described Elderly patient elderly patients Epidemics epidemiological epidemiological data explain expression Genetic genomic sequence Government Haplotype help Human Hypothesis immune implication infected patient Infection innate immune Innate immunity interferon majority Mutagenesis occurred Patient predicted proportion response SARS-CoV-2 SARS-CoV-2 epidemic SARS-CoV-2 genome SARS-CoV-2 genomes stimulated Support tested Vaccine development Vaccine development. variant Victoria Wave [DOI] 10.1111/sji.13100 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in PigsResearch Article Published on 2021-09-212022-10-29 Journal: mBio [Category] COVID-19, SARS, [키워드] acute respiratory syndrome addition Administered Adverse reaction Antigen approved B.1.1.7 B.1.351 candidate Combination coronavirus coronavirus disease coronavirus vaccine COVID-19 dose Effectiveness Efficacy expressing HexaPro Immunity immunogenic immunogenicity include induce intramuscular intranasal intranasally mucosal NDV newcastle disease virus P.1 pig pig model PIGS prefusion conformation proline substitution prolines reactivity responses Safe Safety SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 vaccine Serum neutralizing antibody spike spike variant tested the vaccine Vaccine [DOI] 10.1128/mBio.01908-21 PMC 바로가기 [Article Type] Research Article